Literature DB >> 9263379

Changes in body weight with chronic, high-dose gabapentin therapy.

J C DeToledo1, C Toledo, J DeCerce, R E Ramsay.   

Abstract

The authors reviewed changes in body weight in 44 patients treated with Gabapentin (GPN) for a period of 12 or more months. All patients had a seizure disorder and the dose of GPN was increased aiming at complete seizure control or until side effects limited further increase. Twenty-eight patients were receiving GPN dosages of > 3000 mg/day. Observed changes in body weight were as follows 10 patients gained more than 10% of their baseline weight, 15 patients gained 5% to 10% of baseline, 16 patients had no change, and 3 patients lost 5% to 10% of their initial weight. Weight increase started between the second and the third months of GPN treatment in most patients and tended to stabilize after 6 to 9 months of treatment, although the doses of GPN remained unchanged. Weight gain occurred in patients taking GPN in combination with each of the major antiepileptic drugs including Felbatol and also occurred with GPN monotherapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9263379     DOI: 10.1097/00007691-199708000-00006

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  20 in total

Review 1.  Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.

Authors:  Valentina Medici; Stephen A McClave; Keith R Miller
Journal:  Curr Gastroenterol Rep       Date:  2016-01

2.  Hypothalamic dysfunction of the thrombospondin receptor α2δ-1 underlies the overeating and obesity triggered by brain-derived neurotrophic factor deficiency.

Authors:  Joshua W Cordeira; Jennifer A Felsted; Sarah Teillon; Shabrine Daftary; Micaella Panessiti; Jena Wirth; Miguel Sena-Esteves; Maribel Rios
Journal:  J Neurosci       Date:  2014-01-08       Impact factor: 6.167

Review 3.  The star systems: overview and use in determining antiepileptic drug choice.

Authors:  M J Brodie; P Kwan
Journal:  CNS Drugs       Date:  2001-01       Impact factor: 5.749

Review 4.  Treating epilepsy in the elderly: safety considerations.

Authors:  S Arroyo; G Kramer
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

5.  Alpha2delta-1 in SF1+ Neurons of the Ventromedial Hypothalamus Is an Essential Regulator of Glucose and Lipid Homeostasis.

Authors:  Jennifer A Felsted; Cheng-Hao Chien; Dongqing Wang; Micaella Panessiti; Dominique Ameroso; Andrew Greenberg; Guoping Feng; Dong Kong; Maribel Rios
Journal:  Cell Rep       Date:  2017-12-05       Impact factor: 9.423

Review 6.  The long-term safety of antiepileptic drugs.

Authors:  Athanasios Gaitatzis; Josemir W Sander
Journal:  CNS Drugs       Date:  2013-06       Impact factor: 5.749

Review 7.  Preventive treatment of migraine: effect on weight.

Authors:  William B Young
Journal:  Curr Pain Headache Rep       Date:  2008-06

Review 8.  Effect of antiepileptic drugs on bodyweight: overview and clinical implications for the treatment of epilepsy.

Authors:  Victor Biton
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

9.  Obesity in Women: Insights for the Clinician.

Authors:  Zujaja Tauqeer; Gricelda Gomez; Fatima Cody Stanford
Journal:  J Womens Health (Larchmt)       Date:  2017-10-27       Impact factor: 2.681

10.  Management of epilepsy in the elderly.

Authors:  Juan José Poza
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.